GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vertex Pharmaceuticals Inc (WBO:VRTX) » Definitions » Net Margin %

Vertex Pharmaceuticals (WBO:VRTX) Net Margin %

: 38.48% (As of Dec. 2023)
View and export this data going back to 2017. Start your Free Trial

Net margin is calculated as Net Income divided by its Revenue. Vertex Pharmaceuticals's Net Income for the three months ended in Dec. 2023 was €888 Mil. Vertex Pharmaceuticals's Revenue for the three months ended in Dec. 2023 was €2,309 Mil. Therefore, Vertex Pharmaceuticals's net margin for the quarter that ended in Dec. 2023 was 38.48%.

The historical rank and industry rank for Vertex Pharmaceuticals's Net Margin % or its related term are showing as below:

WBO:VRTX' s Net Margin % Range Over the Past 10 Years
Min: -127.25   Med: 29.6   Max: 68.8
Current: 36.68


WBO:VRTX's Net Margin % is ranked better than
95.33% of 1027 companies
in the Biotechnology industry
Industry Median: -163.32 vs WBO:VRTX: 36.68

Vertex Pharmaceuticals Net Margin % Historical Data

The historical data trend for Vertex Pharmaceuticals's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vertex Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Margin %
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 28.27 43.70 30.92 37.20 36.68

Vertex Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Net Margin % Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 35.56 29.47 36.73 41.69 38.48

Competitive Comparison

For the Biotechnology subindustry, Vertex Pharmaceuticals's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vertex Pharmaceuticals Net Margin % Distribution

For the Biotechnology industry and Healthcare sector, Vertex Pharmaceuticals's Net Margin % distribution charts can be found below:

* The bar in red indicates where Vertex Pharmaceuticals's Net Margin % falls into.



Vertex Pharmaceuticals Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Vertex Pharmaceuticals's Net Margin for the fiscal year that ended in Dec. 2023 is calculated as

Net Margin=Net Income (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=3319.173/9050.056
=36.68 %

Vertex Pharmaceuticals's Net Margin for the quarter that ended in Dec. 2023 is calculated as

Net Margin=Net Income (Q: Dec. 2023 )/Revenue (Q: Dec. 2023 )
=888.39/2308.731
=38.48 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Vertex Pharmaceuticals  (WBO:VRTX) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.


Vertex Pharmaceuticals Net Margin % Related Terms

Thank you for viewing the detailed overview of Vertex Pharmaceuticals's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Vertex Pharmaceuticals (WBO:VRTX) Business Description

Address
50 Northern Avenue, Boston, MA, USA, 02210
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.